4,778 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by B & T Capital Management DBA Alpha Capital Management

Key Points

• Alpha Capital Management bought 4,778 Regeneron shares worth approximately $2.98 million in the second quarter. Institutional investors now own 83.31% of REGN.
• Regeneron reported quarterly earnings of $14.29 per share and revenue of $4.29 billion, beating estimates and representing 16.7% year-over-year revenue growth. The company also declared a $0.94 quarterly dividend, equating to a 0.5% yield.
• REGN traded near $805.93, close to its 52-week high, while analysts maintained a “Moderate Buy” consensus with an average price target of $801.70. Two directors sold shares totaling $960,000 under pre-arranged Rule 10b5-1 plans.

B & T Capital Management DBA Alpha Capital Management purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,778 shares of the biopharmaceutical company's stock, valued at approximately $2,979,000.

Several other large investors have also bought and sold shares of REGN. MidFirst Bank bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $61,000. BlackRock Inc. bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth about $5,682,636,000. Pallas Capital Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth about $1,197,000. Deutsche Bank AG purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at about $323,249,000. Finally, Perigon Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at about $4,467,000. 83.31% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the sale, the director directly owned 1,703 shares of the company's stock, valued at approximately $1,362,400. This represents a 31.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $320,000.00. Following the completion of the transaction, the director owned 603 shares of the company's stock, valued at $482,400. This trade represents a 39.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,400 shares of company stock valued at $1,090,030 in the last quarter. 6.97% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Stock Up 0.3%

Regeneron Pharmaceuticals stock opened at $805.93 on Tuesday. The firm has a 50 day simple moving average of $679.69 and a 200 day simple moving average of $714.24. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $821.11. The firm has a market capitalization of $82.98 billion, a price-to-earnings ratio of 19.92, a P/E/G ratio of 1.37 and a beta of 0.21.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. During the same quarter in the prior year, the business posted $12.81 earnings per share. The business's quarterly revenue was up 16.7% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be paid a $0.94 dividend. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 9.29%.

Wall Street Analyst Weigh In

A number of analysts recently commented on REGN shares. Sanford C. Bernstein upgraded Regeneron Pharmaceuticals to a "hold" rating in a report on Wednesday, July 29th. Citigroup raised their target price on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a "neutral" rating in a research report on Monday, August 3rd. Barclays lowered their target price on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an "overweight" rating on the stock in a research note on Thursday, April 30th. JPMorgan Chase & Co. cut their price target on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an "overweight" rating on the stock in a report on Monday, May 18th. Finally, Guggenheim increased their price target on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a "buy" rating in a research report on Monday, August 3rd. Sixteen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $801.70.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source